TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2198315
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with WHO/MDT regimen
Study: 31396794
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture therapy (LAT)
Study: 26066346
Drug: Atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Atazanavir (ATV) powder boosted with ritonavir (RTV) liquid plus optimized dual nucleoside reverse-transcriptase inhibitor (NRTI) background therapy
Study: 21875474
Drug: Yanshu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanshu injection combined with IMRT and concomitant chemotherapy
Study: 21875474
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IMRT and concurrent chemotherapy)
Study: 19335225
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of hand cream (cornstarch and ethanol)
Study: 16449273
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of acute bronchodilators
Study: 15038168
Drug: Glucocorticosteroid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticosteroid administration
Study: 11156667
Drug: Atrioventricular modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrioventricular modifying drugs and VVI pacemaker
Study: 3538487
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/day for 14 days)
Study: 3538487
Drug: Steroid response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Steroid response
Study: 24959794
Drug: Relaxation breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation breathing and progressive muscle relaxation (twice a day for 8 weeks)
Study: 22428471
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg plus hyperbaric bupivacaine 2.5 mg (Group BF)
Study: 18523382
Drug: Mouth rinsing
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth rinsing solution (0.2% NaF)
Study: 18523382
Drug: Tablet (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (0.75 mg F)
Study: 16419491
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (Group B)
Study: 12585791
Drug: Slider-Board (SB)
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slider-Board (SB) therapy and Standardized Exercises (SEs)
Study: 12585791
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (CPM, SB therapy, SEs)
Study: 10539832
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa inhibitor (eptifibatide)
Study: 1817618
Drug: Thiopentone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 0.5 mg kg‐1
Study: 1817618
Drug: Propofol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.25 mg kg‐1
Study: 30991137
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa (30 mg/kg/day)
Study: 28799861
Drug: No intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intra-arterial therapy (COVES = 0)
Study: 22664976
Drug: IDX375 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX375 200 mg BID
Study: 22664976
Drug: IDX375 (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX375 (25-200 mg single ascending doses)
Study: 18718110
Drug: Multidisciplinary pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary pain treatment allocation protocol
Study: 17578470
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (128 mg slow‐release magnesium stearate)
Study: 31265756
Drug: Parenteral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral sedation
Study: 31265756
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than one type of parenteral sedation administered within 60 minutes
Study: 28425449
Drug: Placebo-pill treatment
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-pill treatment
Study: 25458637
Drug: rhG‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF plus empirical antibiotics (Group I)
Study: 25458637
Drug: Empirical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotics alone (Group II)
Study: 9205016
Drug: Nicorandil 5
Normalized name: nicorandil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 5 mg tid
Study: 3330528
Drug: ST 567
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST 567 3 X 30 mg
Study: 3330528
Drug: Propranolol 3
Normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 3 X 40 mg
Study: 30924578
Drug: basal-only insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: basal-only insulin
Study: 28620916
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Ketamine 0.2 mg/kg, Ketamine 0.4 mg/kg, Saline)
Study: 26571892
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Tianshu (ST 25), Fujie (SP 14) with dense‐disperse wave (2Hz/15 Hz, 0.1 to 1.0 mA) and Shangjuxu (ST 37) needled, treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Study: 26571892
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture (sham‐EA) at sites lateral to Tianshu (ST 25) and Fujie (SP 14), and shallow needling at lateral Shangjuxu (ST 37), treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Study: 18454508
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Study: 18454508
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Study: 11006795
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 60 mg/day orally
Study: 10163482
Drug: Jet spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jet spacer with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Study: 10163482
Drug: Standard actuator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard actuator with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Study: 1614687
Drug: Anti-DIM medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-DIM medication, vitamins, and combined regimen
Study: 6692967
Drug: Peroral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral iron therapy (200 mg Fe++ daily)
Study: 30926104
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with orthodontic treatment
Study: 30926104
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (simulated LLLT with orthodontic treatment)
Study: 22892585
Drug: Avagacestat 25
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 25 mg daily
Study: 22892585
Drug: Avagacestat 50
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 50 mg daily
Study: 22892585
Drug: Avagacestat 100
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 100 mg daily
Study: 22892585
Drug: Avagacestat 125
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 125 mg daily
Study: 17389702
Drug: Lugol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol solution treatment (group 1, n = 17)
Study: 17389702
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative treatment with Lugol solution (group 2, n = 19)
Study: 2269915
Drug: Autogenous bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous bone implant
Study: 29159691
Drug: Vehicle samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle samples (aqueous (AQ) cream)
Study: 19064973
Drug: Neoadjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks for two cycles, followed by cisplatin 40 mg/m(2)/wk concurrent with radiotherapy
Study: 14997082
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 30 mg x kg(‐1)
Study: 14997082
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg x kg(‐1) followed by infusion of 1 mg x kg(‐1) h(‐1)
Study: 7751258
Drug: Lithium (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (mean optimal daily dose: 1,248 mg, mean serum level: 1.12 mEq/L)
Study: 2346341
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (r-hGH)
Study: 341338
Drug: Clotrimazole 7-day
Normalized name: Quality Choice Clotrimazole 7-Day Treatment 1% Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 7-day treatment
Study: 341338
Drug: Clotrimazole 14-day
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 14-day treatment
Study: 341338
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 14-day treatment
Study: 31612359
Drug: Inhaled methoxyflurane
Normalized name: methoxyflurane Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methoxyflurane 3 mL
Study: 31612359
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment (SAT) - IV morphine 0.1 mg/kg for severe pain (NRS ≥ 7); IV paracetamol 1 g or IV ketoprofen 100 mg for moderate pain (NRS 4-6)
Study: 24749263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 25) with multimodal analgesia (paracetamol, tramadol, ketoprofen)
Study: 15927414
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (controls) excluding Grade 1 with superficial myometrial invasion
Study: 10553846
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 9 mg with fentanyl 20 microg
Study: 10553846
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 9 mg with fentanyl 20 microg
Study: 8744464
Drug: Ceftizoxime 1
Normalized name: ceftizoxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 1 g every 12 hours for two doses
Study: 8744464
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g every 24 hours for two doses
Study: 6350878
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (azathioprine and prednisone)
Study: 17657970
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy using 'Dovolenskaya' mineral water
Study: 7625344
Drug: 0.8 g.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Study: 7625344
Drug: 1.0 g.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Study: 7625344
Drug: 1.2 g.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Study: 7625344
Drug: 1.2 g.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g.kg body wt-1.d-1 of a high-quality mixed protein diet (80% from animal sources)
Study: 29151701
Drug: Transcatheter selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter selective SMA urokinase infusion therapy
Study: 21699794
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) in a maximum of 3 infusions of 1000 or 500 mg iron
Study: 21699794
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (IS) with Ganzoni-calculated dosages in up to 11 infusions of 200 mg iron
Study: 17531572
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned glycoprotein IIb/IIIa blockade
Study: 11309551
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of furosemide plus 250 mg of probenecid
Study: 11309551
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of furosemide plus 1000 mg of probenecid
Study: 11309551
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 20 mg of furosemide
Study: 9495430
Drug: Stress hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stress hormone cocktail (epinephrine, cortisol, glucagon, angiotensin II, and vasopressin) administered intravenously for 24 hours
Study: 2666238
Drug: Nifuroxazide 400
Normalized name: nifuroxazide 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifuroxazide 400 mg twice daily for 5 days
Study: 29665619
Drug: Pomegranate Extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate Extract (PE) - D2 (656 mg phenolics)
Study: 28376767
Drug: 20,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU vitamin D3 weekly
Study: 26132895
Drug: 6.4% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% sucrose solution (SUC)
Study: 21599832
Drug: High insertion
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High insertion torque implants (MIT > 70 Ncm, mean = 110.6 Ncm, range: 70.8‐176 Ncm)
Study: 21599832
Drug: Low insertion
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low insertion torque implants (control group, MIT between 30 and 50 Ncm, mean = 37.1 Ncm)
Study: 21436223
Drug: Sublingual cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual cannabis extract (maximum of 10.8 mg tetrahydrocannabinol and 10 mg cannabidiol)
Study: 18472662
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment episode
Study: 18472662
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment after initial outpatient episode
Study: 18472662
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment only
Study: 18472662
Drug: Various combinations
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combinations of outpatient, intensive outpatient, and residential treatment
Study: 10897061
Drug: IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN plus NAC (3MU IFN-alpha thrice weekly plus NAC 1800 mg daily)
Study: 1420739
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine nocte
Study: 31728054
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous methotrexate (IV MTX) infusion (1 g/m2)
Study: 31728054
Drug: 4-hour intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour intravenous methotrexate (IV MTX) infusion (2 g/m2)
Study: 20238247
Drug: Modified-release esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release esomeprazole 60 mg od
Study: 20238247
Drug: Modified-release esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release esomeprazole 80 mg od
Study: 20238247
Drug: Modified-release esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release esomeprazole 40 mg od
Study: 20238247
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation esomeprazole 20 mg bid
Study: 20238247
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation esomeprazole 40 mg bid
Study: 7992938
Drug: Fraxiparine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparine (0.3 mL, 3,075 anti Xa IU per day, one daily subcutaneous injection)
Study: 7992938
Drug: Calciparine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calciparine (0.2 mL t.i.d., 15,000 IU per day, one subcutaneous injection)
Study: 2514323
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (Benzodiazepine antagonist)
Study: 29170073
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fentanyl (control)
Study: 25255113
Drug: Vertical scar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical scar reduction (for reductions less than 500 g)
Study: 22221076
Drug: telcagepant (280-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant (280-mg tablet/300-mg capsule)
Study: 20669013
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily for 3 days)
Study: 20669013
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 HEMs and PMs
Study: 20669013
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 EMs
Study: 17573359
Drug: AutoCapture devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoCapture devices with steroid‐eluting epicardial leads
Study: 16288378
Drug: vCP205 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 vaccine formulation (10(6.08) TCID(50))
Study: 16288378
Drug: vCP205 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 vaccine formulation (10(6.33) TCID(50))
Study: 16288378
Drug: vCP205 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 vaccine (both formulations)
Study: 11843746
Drug: Oxygen at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen at 2 l x min(‐1) by nasal cannulae
Study: 19496103
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid)
Study: 11915064
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (10 mL/h)
Study: 11915064
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (5 mL/h basal rate with 5 mL bolus every 60 minutes)
Study: 1978475
Drug: Remoxipride CR
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride CR (385 mg daily)
Study: 1978475
Drug: Haloperidol (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (17 mg daily)
Study: 31800542
Drug: Crofelemer (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer (125 mg)
Study: 28131677
Drug: Routine antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibacterial therapy
Study: 17699383
Drug: Dependence on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependence on activity of daily living scale
Study: 19089782
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days
Study: 15219887
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days + phytoestrogens (PE) 1500 mg daily for 10 days
Study: 10798461
Drug: Combined behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined behavioral and drug therapy (biofeedback-assisted behavioral training followed by oxybutynin chloride titrated from 2.5 mg to 15 mg daily)
Study: 10798461
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (oxybutynin chloride)
Study: 10798461
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug and behavioral treatment
Study: 1305819
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 6 puffs (1500 micrograms) of terbutaline
Study: 1305819
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 2 puffs (500 micrograms) of terbutaline at 15-minute intervals
Study: 1305819
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 2 puffs (500 micrograms) of terbutaline at 5-minute intervals